Cyclacel Pharmaceuticals, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CYCC research report →
Companywww.cyclacel.com
Cyclacel Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors.
- CEO
- Sing Ee Wong
- IPO
- 2004
- Employees
- 12
- HQ
- Berkeley Heights, NJ, US
Price Chart
Valuation
- Market Cap
- $10.61M
- P/E
- -1.69
- P/S
- 1.38
- P/B
- 0.78
- EV/EBITDA
- 0.34
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 18.36%
- Op Margin
- -238.49%
- Net Margin
- -204.20%
- ROE
- -51.20%
- ROIC
- -53.74%
Growth & Income
- Revenue
- $747.00K · 1637.21%
- Net Income
- $-2,998,000 · 73.26%
- EPS
- $-6.45 · -374.26%
- Op Income
- $-8,427,000
- FCF YoY
- 40.30%
Performance & Tape
- 52W High
- $597.60
- 52W Low
- $3.08
- 50D MA
- $8.11
- 200D MA
- $44.19
- Beta
- 0.16
- Avg Volume
- 1.81M
Get TickerSpark's AI analysis on CYCC
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 5, 25 | Kua Khai Loon | sell | 19,054 |
| Sep 4, 25 | Yap Kim Choy | other | 186,465 |
| Sep 4, 25 | Yap Kim Choy | other | 186,465 |
| Sep 4, 25 | Kua Khai Loon | other | 186,465 |
| Sep 4, 25 | Kua Khai Loon | other | 186,465 |
| Sep 4, 25 | Ong Yee Lung | other | 186,465 |
| Sep 4, 25 | Ong Yee Lung | other | 186,465 |
| Sep 1, 25 | Ong Yee Lung | other | 0 |
| Jun 20, 25 | Ong Yee Lung | other | 218,000 |
| Jun 20, 25 | Ong Yee Lung | other | 218,000 |
Our CYCC Coverage
We haven't published any research on CYCC yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate CYCC Report →